Kent Pharmaceuticals Limited has been acquired by DCC Plc
Dublin-based support services company, DCC plc, has acquired 100% of Kent Pharmaceuticals Ltd., the UK's largest independent generic pharmaceuticals manufacturer, for US$93 million.
DCC is a sales, marketing, distribution and business support services company. It operates in five segments: DCC Energy, DCC SerCom, DCC Healthcare, DCC Environmental, and DCC Food & Beverage.
DCC plans to combine Kent Pharmaceuticals with its healthcare division, DCC Healthcare, to create a pharma business with aggregate revenues approaching US$247 million and to become a leader in the British and Irish generic pharmaceutical market. Mike Overy, Kent Pharmaceutical’s managing director, said: “The shareholders believe this transaction provides a fantastic opportunity to continue the growth and development of Kent Pharmaceuticals with a partner that is committed to expanding into the generic pharmaceutical market.”
Oaklins Cavendish, based in the UK, advised Kent Pharmaceuticals in this transaction. There had been a significant amount of consolidation in the sector in recent months and this deal creates a substantial UK generic pharmaceutical business with excellent international expansion opportunities.
Talk to the deal team
Related deals
Bayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn moreSaideep Healthcare and Research has raised equity
Saideep Healthcare and Research Private Limited has successfully completed a fundraising. This funding will help Saideep become a leading healthcare brand, offering advanced specialties across the region. The funds from this collaboration will be used to diversify into new and complex specialties, expand infrastructure and meet the growing demand for high-quality healthcare services in Western India.
Learn moreVivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn more